"We look forward to sharing the clinical results in July and, if promising, quickly initiating the phase 2 portion of the trial".
A randomized controlled trial will include 130 healthy people between the ages of 18-59 during the new coronavirus vaccine test. Placebo will be received by some of the participating individuals, while others will receive the vaccine candidate for Novavax. The company further indicated that that "NVX-CoV2373 includes Novavax' proprietary Matrix-M adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies". Moreover, if the product can beat Sanofi's flu vaccine Fluzone in the clinical trials, then it could also create greater confidence for its coronavirus vaccine. Phase 2 is then expected to expand to several other countries including the US and will assess immunity, safety and COVID-19 disease reduction in a broader age range of patients.
According to Griffin, Novavax has already begun planning the large-scale manufacturing of the vaccine should the trials prove successful, with an expected capacity to produce 100 million doses by the end of the year.
"We injected the vaccine into 13 long-tailed macaques on Saturday".
University of Oxford in England developed and licensed the vaccine candidate to AstraZeneca.
About a dozen experimental vaccines against the coronavirus are in early stages of testing or poised to start, mostly in China, the USA and Europe.
Human trials are set to proceed to their second and third phases - however with coronavirus an infection charges in the United Kingdom falling sharply, Oxford scientist Adrian Hill has warned that there is probably not sufficient folks in the United Kingdom to catch the virus for a conclusive trial to be performed. Sinopharm, one of Sinovac and another of the Chinese Academy of Medical Sciences and CanSino Biologics Company.
In addition, he said, the vaccine did not elicit a strong immune response. "CEPI's priority in building our portfolio has been to focus on vaccine candidates with the potential to be developed at speed and scale and made globally accessible", Hatchett said in a statement. "Explains the person in charge of the work, Wei Chen, from the Institute of Biotechnology in Beijing, China". The Maryland-based company is one of several biotech companies concerned with developing a vaccine against SARS-CoV-2, the virus that triggered coronavirus.
Offit said the immunogenicity data was "not impressive", especially since all of the doses - even the "low" dose - were actually very high, he said. The trial is a two-part randomized, observer-blinded, placebo-controlled study created to evaluate the immunogenicity and safety of the vaccine with or without Matrix-M adjuvant in healthy participants ≥ 18 to 59 years of age. "The challenges in the development of a COVID-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19".
